Inhibitors of Bacterial DNA Synthesis

Fluoroquinolones are synthetic antibiotics that target DNA gyrase and topoisomerase IV, two enzymes essential for bacterial DNA replication. These drugs trap the enzyme-DNA complexes in their cleaved state, preventing strand religation and causing lethal double-strand breaks. This accumulation of broken DNA fragments disrupts critical cellular processes, ultimately leading to bacterial cell death.

DNA gyrase introduces negative supercoils in the bacterial chromosome during replication by cutting DNA strands, passing other segments through, and resealing them. Topoisomerase IV cuts DNA strands after replication to separate the two circular daughter chromosomes. Both enzymes are critical for resolving DNA supercoiling and unlinking chromosomes, making them ideal antibiotic targets.

Fluoroquinolones primarily inhibit DNA gyrase in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria. This selectivity for different target enzymes in each bacterial type enables broad-spectrum coverage. Additionally, fluoroquinolones efficiently penetrate bacterial cells via porins and can target intracellular organisms like Legionella and Mycoplasma.

Specific fluoroquinolone agents like ciprofloxacin, levofloxacin, and moxifloxacin are employed to treat urinary tract infections, respiratory infections, skin and soft tissue infections, osteomyelitis, and hospital-acquired pneumonia. Their broad-spectrum activity and cellular penetration make them valuable for infections caused by diverse bacterial pathogens, including intracellular organisms.

Fluoroquinolones can cause tendinitis and tendon rupture, particularly the Achilles tendon, especially in elderly patients and those on corticosteroids. Central nervous system effects range from headache and insomnia to seizures and psychosis. Additional concerns include peripheral neuropathy, aortic aneurysm risk in older adults, and Clostridioides difficile-associated colitis.

Due to serious adverse effects and rapidly emerging antibiotic resistance, fluoroquinolones are now reserved for conditions where benefits outweigh risks or when first-line agents fail. Regulatory bodies like the FDA and EMA recommend limited use for uncomplicated infections and emphasize antimicrobial stewardship to minimize resistance development and adverse outcomes.

Unlike inhibitors of bacterial protein synthesis or cell wall synthesis, fluoroquinolones directly target DNA replication by stabilizing enzyme-DNA cleavage complexes. This mechanism causes double-strand breaks rather than disrupting protein production or cell wall integrity. The selective toxicity to bacteria stems from structural differences between bacterial and eukaryotic topoisomerases.